Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19
Status:
Withdrawn
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
No optimal antiviral intervention has been yet validated to treat COVID-19 disease.
Comorbidities, such as older age, obesity, diabetes, history of cardiovascular diseases are
associated with poor prognosis.
This study aims to evaluate the efficacy of two experimental antiviral treatments, compared
to standard of care (SOC), to prevent clinical worsening, hospitalization or death at day 14
in adults with documented SARS-CoV-2 infection, asymptomatic or with symptoms lasting less
than 8 days, and associated comorbidities without any severity criteria of the disease at
inclusion.
Participants will be randomized to receive SOC alone or SOC + hydroxychloroquine 200 mg three
times a day during 10 days or SOC + association of niclosamide 2 g at J1 then 500 mg two
times a day with diltiazem 60 mg three times a day during 10 days. Efficacy and tolerance of
each treatments will be compared across the three treatment groups during the 28 days of
follow-up.